The bioreactor systems produced by Hybrid Organ are based on recent scientific developments, which have opened up new areas of operation in biomedicine. They allow a broad clinical applicability in intensive care medicine and offer a basis in medical biotechnology for other substance producing technologies via primary cells. New market segments with high market potential have opened up. A change of paradigm has already been generated by the MELS (Modular Extracorporeal Liver System).
A sustainable competitive advantage can be achieved through innovative bioreactor developments with various unique selling positions, USPs.
Unique Selling Positions
In vitro tissue culture has been based almost solely on the cultivation of cell monolayers on cell culture vessels. Although conventional cultures are easy to handle and can be managed at low expenditure, the in vitro simulation of organ like conditions is not sufficient: it is the lack of three-dimensional structures and of physiological cell matrix interactions that direct the cell metabolism and gene expression towards a differentiated state.
The Hybrid Organ bioreactors address these problems and enable co-culturing of different cell populations at a higher density and in 3D formation of organ-like cell aggregations. They also allow the cells to produce bio-matrix in the neo-tissues. The unique architecture of the bioreactors, coupled with the options of decentralized medium perfusion, nutrient and metabolite exchange with low gradients, and efficient integrated oxygenation make this possible.